The PRISM-I trial promoted by Gustave Roussy and Prism began on October 5, 2021.
The objectives of this study are to:
i. define the effectiveness of anti-PDL1 antibodies at 6 weeks,
ii. decipher the immune response at the single cell and spatial level.
200 patients with triple negative early breast cancer will be recruited.
This study is supported by the arc foundation.